MedDataX Logo

First-in-Human Single and Multiple Dose of GLPG1972

NCT ID: NCT02612246

Last Updated: 2016-07-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of GLPG1972 given to healthy subjects, compared to placebo. Also, the safety and tolerability of multiple ascending oral doses of GLPG1972 given to healthy subjects daily for 14 days compared to placebo, will be evaluated.

Furthermore, during the course of the study after single and multiple oral dose administrations, the amount of GLPG1972 present in the blood and urine (pharmacokinetics) will be characterized.

The effect of food on the pharmacokinetics of GLPG1972 will also be evaluated. The potential of cytochrome P450 (CYP)3A4 interaction after repeated dosing with GLPG1972 will be explored as well.

During the course of the study after multiple oral dose administrations, the effect of GLPG1972 on biomarkers present in the blood (pharmacodynamics) will be characterized.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GLPG1972 single dose

Single oral dose of GLPG1972 solution - ascending doses

Group Type EXPERIMENTAL

GLPG1972 single ascending doses

Intervention Type DRUG

single dose, oral solution

Placebo single dose

Single oral dose of placebo solution

Group Type PLACEBO_COMPARATOR

Placebo single dose

Intervention Type DRUG

single dose, oral solution, matching placebo

GLPG1972 multiple doses

Multiple oral doses of GLPG1972 solution - ascending doses

Group Type EXPERIMENTAL

GLPG1972 multiple ascending doses

Intervention Type DRUG

multiple doses, daily for 14 days, oral solution

Placebo multiple doses

Multiple oral doses of placebo solution

Group Type PLACEBO_COMPARATOR

Placebo multiple doses

Intervention Type DRUG

multiple doses, daily for 14 days, oral solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLPG1972 single ascending doses

single dose, oral solution

Intervention Type DRUG

Placebo single dose

single dose, oral solution, matching placebo

Intervention Type DRUG

GLPG1972 multiple ascending doses

multiple doses, daily for 14 days, oral solution

Intervention Type DRUG

Placebo multiple doses

multiple doses, daily for 14 days, oral solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males between 18-50 years of age
* Subjects must have a body mass index between 18-30 kg/m²
* Subjects must be judged to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram and laboratory profile

Exclusion Criteria

* A subject with a known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug
* Concurrent participation or participation within 8 weeks prior to the initial study drug administration in a drug/device investigational research study
* A subject with active drug or alcohol abuse within 2 years prior to the initial study drug administration
* Current sexually active (and/or child wish) male; a contraception method should be used
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Galapagos NV

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ennis Lee, MD

Role: STUDY_DIRECTOR

Galapagos NV

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

SGS LSS Clinical Pharmacology Unit Antwerp

Antwerp, Antwerp, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-004156-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

GLPG1972-CL-101

Identifier Type: -

Identifier Source: org_study_id